Skip to content

Drug interactions

Apalutamide + Tucatinib

Severity: Major

Apalutamide and Tucatinib: major interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Apalutamide may decrease tucatinib exposure since tucatinib is metabolized mainly by CYP2C8 with CYP3A contribution. Lower levels may reduce efficacy in HER2-positive cancer.

What this interaction means in plain words

Apalutamide and Tucatinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Apalutamide belongs to Endocrine; Tucatinib belongs to Oncology.

Evidence level: Moderate

Why it happens

Apalutamide induces CYP3A4 and CYP2C8, increasing tucatinib clearance.

What to do

Avoid concurrent use, as tucatinib labeling advises against strong CYP3A or CYP2C8 inducers. Use an alternative antiandrogen if possible.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Apalutamide and Tucatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Apalutamide with Tucatinib?

MediHelp rates the interaction as major. Apalutamide and Tucatinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Apalutamide may decrease tucatinib exposure since tucatinib is metabolized mainly by CYP2C8 with CYP3A contribution. Lower levels may reduce efficacy in HER2-positive cancer.

How serious is the interaction between Apalutamide and Tucatinib?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid concurrent use, as tucatinib labeling advises against strong CYP3A or CYP2C8 inducers. Use an alternative antiandrogen if possible.

What other medicines interact with Apalutamide?

MediHelp also lists interactions of Apalutamide with, for example, Cabotegravir, Cobicistat, Doravirine. The full list is on the Apalutamide page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in